These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
308 related articles for article (PubMed ID: 25609545)
1. Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma. Zukotynski K; Yap JT; Giobbie-Hurder A; Weber J; Gonzalez R; Gajewski TF; O'Day S; Kim K; Hodi FS; Van den Abbeele AD Cancer Imaging; 2014 Nov; 14(1):30. PubMed ID: 25609545 [TBL] [Abstract][Full Text] [Related]
2. ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression. Van den Abbeele AD; Gatsonis C; de Vries DJ; Melenevsky Y; Szot-Barnes A; Yap JT; Godwin AK; Rink L; Huang M; Blevins M; Sicks J; Eisenberg B; Siegel BA J Nucl Med; 2012 Apr; 53(4):567-74. PubMed ID: 22381410 [TBL] [Abstract][Full Text] [Related]
3. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. Prior JO; Montemurro M; Orcurto MV; Michielin O; Luthi F; Benhattar J; Guillou L; Elsig V; Stupp R; Delaloye AB; Leyvraz S J Clin Oncol; 2009 Jan; 27(3):439-45. PubMed ID: 19064982 [TBL] [Abstract][Full Text] [Related]
4. Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study. Sachpekidis C; Larribere L; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A; Hassel JC Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):386-96. PubMed ID: 25359635 [TBL] [Abstract][Full Text] [Related]
5. [18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib]. Banzo I; Quirce R; Martínez-Rodríguez I; Jiménez-Bonilla JF; Sainz-Esteban A; Barragán J; Portilla-Quattrociocchi H; Carril JM Rev Esp Med Nucl; 2008; 27(3):168-75. PubMed ID: 18570858 [TBL] [Abstract][Full Text] [Related]
6. Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography. Heinicke T; Wardelmann E; Sauerbruch T; Tschampa HJ; Glasmacher A; Palmedo H Anticancer Res; 2005; 25(6C):4591-4. PubMed ID: 16334147 [TBL] [Abstract][Full Text] [Related]
7. Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response--an AGITG study. Goldstein D; Tan BS; Rossleigh M; Haindl W; Walker B; Dixon J Oncology; 2005; 69(4):326-32. PubMed ID: 16293972 [TBL] [Abstract][Full Text] [Related]
8. Value of FDG-PET for monitoring treatment response in patients with advanced GIST refractory to high-dose imatinib. A multicenter GEIS study. Fuster D; Ayuso JR; Poveda A; Cubedo R; Casado A; Martínez-Trufero J; López-Pousa A; Del Muro XG; Lomeña F; Maurel J; Pons F Q J Nucl Med Mol Imaging; 2011 Dec; 55(6):680-7. PubMed ID: 21150863 [TBL] [Abstract][Full Text] [Related]
9. Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report. Rapisuwon S; Parks K; Al-Refaie W; Atkins MB Melanoma Res; 2014 Oct; 24(5):509-11. PubMed ID: 25003536 [TBL] [Abstract][Full Text] [Related]
11. Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab. Skougaard K; Nielsen D; Jensen BV; Hendel HW J Nucl Med; 2013 Jul; 54(7):1026-31. PubMed ID: 23572497 [TBL] [Abstract][Full Text] [Related]
12. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. Choi H; Charnsangavej C; Faria SC; Macapinlac HA; Burgess MA; Patel SR; Chen LL; Podoloff DA; Benjamin RS J Clin Oncol; 2007 May; 25(13):1753-9. PubMed ID: 17470865 [TBL] [Abstract][Full Text] [Related]
13. FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma. Tan AC; Emmett L; Lo S; Liu V; Kapoor R; Carlino MS; Guminski AD; Long GV; Menzies AM Ann Oncol; 2018 Oct; 29(10):2115-2120. PubMed ID: 30137228 [TBL] [Abstract][Full Text] [Related]
14. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662 [TBL] [Abstract][Full Text] [Related]
15. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. Holdsworth CH; Badawi RD; Manola JB; Kijewski MF; Israel DA; Demetri GD; Van den Abbeele AD AJR Am J Roentgenol; 2007 Dec; 189(6):W324-30. PubMed ID: 18029844 [TBL] [Abstract][Full Text] [Related]
16. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. Hodi FS; Corless CL; Giobbie-Hurder A; Fletcher JA; Zhu M; Marino-Enriquez A; Friedlander P; Gonzalez R; Weber JS; Gajewski TF; O'Day SJ; Kim KB; Lawrence D; Flaherty KT; Luke JJ; Collichio FA; Ernstoff MS; Heinrich MC; Beadling C; Zukotynski KA; Yap JT; Van den Abbeele AD; Demetri GD; Fisher DE J Clin Oncol; 2013 Sep; 31(26):3182-90. PubMed ID: 23775962 [TBL] [Abstract][Full Text] [Related]
17. The role of interim Sachpekidis C; Anwar H; Winkler J; Kopp-Schneider A; Larribere L; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1289-1296. PubMed ID: 29478079 [TBL] [Abstract][Full Text] [Related]
18. Early response assessment in gastrointestinal stromal tumors with FDG PET scan 24 hours after a single dose of imatinib. Shinto A; Nair N; Dutt A; Baghel NS Clin Nucl Med; 2008 Jul; 33(7):486-7. PubMed ID: 18580237 [TBL] [Abstract][Full Text] [Related]
19. [Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib]. Hong JL; Li J; Li J; Shen L Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):386-90. PubMed ID: 22932406 [TBL] [Abstract][Full Text] [Related]